<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346085</url>
  </required_header>
  <id_info>
    <org_study_id>ECIT-1</org_study_id>
    <nct_id>NCT01346085</nct_id>
  </id_info>
  <brief_title>Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation</brief_title>
  <acronym>ECIT-1</acronym>
  <official_title>A Multi-step Trial Towards Single Donor Islet Transplantation in Type 1 Diabetic Patients, Using Calcineurin Inhibitor-free Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our final objective is to develop an adoptive therapy with tolerogenic donor-specific Tr1
      cells in T1D patients undergoing pancreatic islet transplantation (Tx). The achievement of
      this objective depends by the availability of an immunosuppressive treatment (IS) compatible
      with the survival, function, and expansion of the transferred Tr1 cells. For this purpose the
      investigators design a CNI-free single-group, phase 1-2 trial excluding the ATG or anti-CD25
      induction therapy after the 1st islet infusion
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed the clinical trial as a single-arm, phase 1-2 trial conducted in two transplant
      centers (San Raffaele Scientific Institute, Milan, Italy; Cell Isolation and Transplantation
      Center, University of Geneva, Geneva, Switzerland) which used a common protocol for islet
      preparation, post-transplantation patient management and data collection. The trial is
      exploratory in nature and the target enrollment is 10 patients. The recruitment is
      competitive between the two centers and each patient is to receive at least 10,000 IE/kg. Up
      to three islet infusions are allowed per patients until insulin independence is reached,
      provided that partial islet function (i.e., fasting C-peptide ≥0.3 ng/mL) is maintained
      between infusions. We planned an individual follow-up of 3 years after the last islet
      infusion.

      Patients with type 1 diabetes are eligible for this study. Major criteria for inclusion are:
      age 18-65 years; type 1 diabetes with onset &lt;40 years of age; insulin treatment of at least 5
      years at the time of enrollment; stimulated C-peptide in response to arginine &lt;0.5 ng/ml;
      multiple (three or more) daily insulin injections or Continuous Subcutaneous Insulin
      Infusion; self-blood glucose monitoring ≥3 times/day; high glycemic instability and/or
      hypoglycemia unawareness; inability to consistently attain a glycated hemoglobin target of
      &lt;7.5 % without severe hypoglycemia (defined as an hypoglycemic episode requiring the
      assistance by another person for its resolution) in the past 36 months despite medical
      management by a diabetes specialist. Major criteria for exclusion are: HbA1c &gt;12%; BMI &gt;30
      kg/m2, or insulin requirement &gt; 0.8 IU/kg/day; poorly controlled hypertension; untreated
      proliferative diabetic retinopathy; presence or history of macroalbuminuria (&gt;300mg/g day) or
      estimated glomerular filtration rate &lt;60 ml/min/1.73 m2 for females or &lt;70 ml/min/1.73 m2 for
      males.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion</measure>
    <time_frame>3 year</time_frame>
    <description>Insulin independence is defined as no need for exogenous insulin, with adequate glycemic control [i.e., glycated hemoglobin &lt;7% (normal range 3.5 - 6.0%), fasting glucose levels not exceeding 140 mg/dL (7.8 mmol/L) more than three times per week and 2-hour postprandial levels not exceeding 180 mg/dL (10 mmol/L) more than four times per week].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Independence With Adequate Glycemic Control Throughout Follow-up</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated Hemoglobin Levels Throughout Follow-up</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal and Stimulated Blood C-peptide Levels in Response to Arginine Challenge Throughout Follow-up</measure>
    <time_frame>up to 3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Reduction in Insulin Requirement Compared to Baseline</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Hypoglycemic Events Since Completion of Transplant</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Adverse Event Throughout Follow-up</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Among study participants there were no reports of death, post-transplantation lymphoproliferative disease, cancer, or opportunistic infections. There was no evidence of cytomegalovirus disease, infection or serological activation (CMV early antigens negative during the whole follow-up), nor of Epstein-Barr clinical and serological reactivation (all patients were antibodies anti EBV positive before transplant, as per the inclusion criteria).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>CNI-free single-group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNI free immunosuppression</intervention_name>
    <description>Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).</description>
    <arm_group_label>CNI-free single-group</arm_group_label>
    <other_name>Kineret, Rapamune, Thymoglobulin, Myfortic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged 18-65yr

          -  ability to provide written informed consent and comply with the study protocol
             procedures

          -  clinical history of type 1 diabetes with onset &lt;40yr of age, on insulin for at least
             5yr at the time of enrollment

          -  absent stimulated C-peptide (&lt;0.5ng/ml) in response to arginine

          -  multiple (three or more) daily insulin injections or insulin pump therapy

          -  self blood glucose monitoring ≥3 times/day, supervised by a specialist physician

          -  high glycemic instability and hypoglycemia unawareness

          -  inability to consistently attain a HbA1c &lt; 7.5 % target without experiencing severe
             hypoglycemia (assistance by another person) in the past 36 months despite appropriate
             medical management.

        Exclusion Criteria:

          -  HbA1c &gt;12%

          -  BMI &gt;30 kg/m2, or insulin requirement of &gt; 0.8 IU/kg/day;

          -  poorly controlled hypertension;

          -  untreated proliferative diabetic retinopathy;

          -  presence or history of macroalbuminuria (&gt;300mg/g day) or measured glomerular
             filtration rate &lt;60 ml/min/1.73 m2 for females and &lt;70 ml/min/1.73 m2 for males

          -  for female participants: positive pregnancy test, presently breast-feeding, or
             unwilling to use effective contraceptive measures for the duration of the study and 3
             months after discontinuation

          -  for male participants: intent to procreate during the duration of the study or within
             3 months after discontinuation or unwillingness to use effective measures of
             contraception;

          -  any history of malignancy within the previous 5 years, except for completely resected
             squamous or basal cell carcinoma of the skin;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Piemonti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Centro San Raffaele del Monte Tabor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry Berney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitè de Geneve</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Secchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione Centro San Raffaele del Monte Tabor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paola Maffi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cantro San Raffaele del Monte Tabor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitè de Geneve</name>
      <address>
        <city>Geneve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Piemonti L, Maffi P, Monti L, Lampasona V, Perseghin G, Magistretti P, Secchi A, Bonifacio E. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia. 2011 Feb;54(2):433-9. doi: 10.1007/s00125-010-1959-6. Epub 2010 Nov 3.</citation>
    <PMID>21046356</PMID>
  </reference>
  <results_reference>
    <citation>Melzi R, Maffi P, Nano R, Sordi V, Mercalli A, Scavini M, Secchi A, Bonifacio E, Piemonti L. Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans. Islets. 2009 Jul-Aug;1(1):42-9. doi: 10.4161/isl.1.1.8881.</citation>
    <PMID>21084848</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <results_first_submitted>April 9, 2014</results_first_submitted>
  <results_first_submitted_qc>April 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2014</results_first_posted>
  <last_update_submitted>April 9, 2014</last_update_submitted>
  <last_update_submitted_qc>April 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Raffaele</investigator_affiliation>
    <investigator_full_name>Piemonti Lorenzo</investigator_full_name>
    <investigator_title>Director Islet Transplantation Program</investigator_title>
  </responsible_party>
  <keyword>islet transplantation</keyword>
  <keyword>brittle diabetes</keyword>
  <keyword>type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CNI-free Single-group</title>
          <description>CNI free immunosuppression: Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CNI-free Single-group</title>
          <description>CNI free immunosuppression: Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion</title>
        <description>Insulin independence is defined as no need for exogenous insulin, with adequate glycemic control [i.e., glycated hemoglobin &lt;7% (normal range 3.5 - 6.0%), fasting glucose levels not exceeding 140 mg/dL (7.8 mmol/L) more than three times per week and 2-hour postprandial levels not exceeding 180 mg/dL (10 mmol/L) more than four times per week].</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CNI-free Single-group</title>
            <description>CNI free immunosuppression: Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion</title>
          <description>Insulin independence is defined as no need for exogenous insulin, with adequate glycemic control [i.e., glycated hemoglobin &lt;7% (normal range 3.5 - 6.0%), fasting glucose levels not exceeding 140 mg/dL (7.8 mmol/L) more than three times per week and 2-hour postprandial levels not exceeding 180 mg/dL (10 mmol/L) more than four times per week].</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Independence With Adequate Glycemic Control Throughout Follow-up</title>
        <time_frame>up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CNI-free Single-group</title>
            <description>CNI free immunosuppression: Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Independence With Adequate Glycemic Control Throughout Follow-up</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycated Hemoglobin Levels Throughout Follow-up</title>
        <time_frame>up to 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal and Stimulated Blood C-peptide Levels in Response to Arginine Challenge Throughout Follow-up</title>
        <time_frame>up to 3 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Reduction in Insulin Requirement Compared to Baseline</title>
        <time_frame>up to 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Hypoglycemic Events Since Completion of Transplant</title>
        <time_frame>up to 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Adverse Event Throughout Follow-up</title>
        <description>Among study participants there were no reports of death, post-transplantation lymphoproliferative disease, cancer, or opportunistic infections. There was no evidence of cytomegalovirus disease, infection or serological activation (CMV early antigens negative during the whole follow-up), nor of Epstein–Barr clinical and serological reactivation (all patients were antibodies anti EBV positive before transplant, as per the inclusion criteria).</description>
        <time_frame>up to 3 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 years after last islet infusion</time_frame>
      <desc>AEs were recorded according to the “Terminology Criteria for Adverse Events (TCAE) In Trials of Adult Pancreatic Islet Transplantation, Version 4.1 (16 July 2008)” (http://www.isletstudy.org/CITDocs/CIT-TCAE%20V4.pdf).</desc>
      <group_list>
        <group group_id="E1">
          <title>CNI-free Single-group</title>
          <description>CNI free immunosuppression: Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>TCAE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ATG reaction during third infusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>TCAE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Transient liver enzyme increase exceeding 5 times the baseline level</sub_title>
                <description>Transient liver enzyme increase was always observed after each islet infusion, and in 2 out of 20 procedures (10%) the observed increase exceeded 5 times the baseline level</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mouth ulcers</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal conditions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal infection</sub_title>
                <description>Oral or vaginal candidiasis</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lower urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne or rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/bleeding from percutaneous transhepatic portal access</sub_title>
                <description>Procedure-related adverse events included hemorrhage/bleeding from percutaneous transhepatic portal access in 6 of 20 islet infusions (30%)</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Lorenzo Piemonti</name_or_title>
      <organization>Ospedale San Raffaele</organization>
      <phone>+390226432706</phone>
      <email>piemonti.lorenzo@hsr.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

